Skip to main navigation Skip to search Skip to main content

The effect of nitroglycerin on the IUD insertion experience in nulliparous women: A pilot study

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Concern about pain during placement of an intrauterine device (IUD) represents a barrier to use, especially among nulliparous women. We hypothesized that nitroglycerin gel applied vaginally 30 min prior to IUD placement would reduce insertion-related pain. Study design: We designed a randomized, double-blinded, placebo-controlled pilot study to evaluate the efficacy and tolerability of 0.5-mg nitroglycerin gel (1 mL) or identical placebo gel applied vaginally in nulliparous women 30 min prior to IUD placement. The study was limited to women who opted for the levonorgestrel- releasing intrauterine system. Subjects completed a series of 100-mm visual analogue scales at several time points. The primary outcome was subject-reported pain with passage of the IUD through the cervix. Secondary outcomes included subject-reported pain at other time points, provider-reported ease of insertion, side effects, adverse events and need for additional dilation. Results: A total of 24 women were randomized. Baseline characteristics were similar between groups. The mean pain score with IUD deployment was 55.0 mm [standard deviation (SD) = 29.7 mm] in the placebo group and 57.4 mm (SD 22.1 mm) in the nitroglycerin group (p=.82). There was no difference in ease of insertion reported by providers. Two subjects required dilation, one in each group. Conclusion: Vaginal administration of 0.5-mg nitroglycerin gel 30 min prior to IUD placement does not appear to decrease patient-reported procedural pain among nulliparous women or ease of insertion for providers.

Original languageEnglish (US)
Pages (from-to)60-65
Number of pages6
JournalContraception
Volume90
Issue number1
DOIs
StatePublished - Jul 2014

Funding

Author financial disclosures: Dr. Micks is a Nexplanon trainer for Merck. Dr. Jensen has received payments for consulting from Agile Pharmaceuticals, AbbVie Pharmaceuticals, Bayer Healthcare, ContraMed, Evofem Inc, HRA Pharma, Merck Pharmaceuticals, Teva Pharmaceuticals and the Population Council and for giving talks for Bayer and Merck. He has also received research funding from AbbVie, Bayer, the Population Council, the National Institute of Health and the Bill & Melinda Gates Foundation. Dr. Bednarek is on a Bayer advisory board and is a Nexplanon trainer for Merck.

Funders
Bayer Fund
Population Council
AbbVie
Bill and Melinda Gates Foundation
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health

    Keywords

    • Intrauterine device
    • Nitric oxide donor
    • Pain

    ASJC Scopus subject areas

    • Reproductive Medicine
    • Obstetrics and Gynecology

    Fingerprint

    Dive into the research topics of 'The effect of nitroglycerin on the IUD insertion experience in nulliparous women: A pilot study'. Together they form a unique fingerprint.

    Cite this